-
1
-
-
0028817815
-
U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease
-
U.K. Prospective Diabetes Study Group
-
U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
-
(1995)
Diabetes
, vol.44
, pp. 1249-1258
-
-
-
2
-
-
0032742992
-
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
-
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
-
(1999)
J Clin Invest
, vol.104
, pp. 787-794
-
-
Weyer, C.1
Bogardus, C.2
Mott, D.M.3
Pratley, R.E.4
-
3
-
-
64249171985
-
Management of Chinese patients with type 2 diabetes, 1998-2006: The Diabcare-China surveys
-
Pan C, Yang W, Jia W, Weng J, Tian H. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys. Curr Med Res Opin 2009; 25: 39-45.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 39-45
-
-
Pan, C.1
Yang, W.2
Jia, W.3
Weng, J.4
Tian, H.5
-
4
-
-
0038077538
-
Loss of early insulin secretion leads to postprandial hyperglycaemia
-
Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003; 46(Suppl 1): M2-M8.
-
(2003)
Diabetologia
, vol.46
, Issue.SUPPL. 1
-
-
del Prato, S.1
-
5
-
-
34347379097
-
Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial
-
Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, et al. Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007; 9: 558-565.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 558-565
-
-
Li, J.1
Tian, H.2
Li, Q.3
Wang, N.4
Wu, T.5
Liu, Y.6
-
6
-
-
3943054698
-
Restoration of early insulin secretion after a meal in type 2 diabetes: Effects on lipid and glucose metabolism
-
Dimitriadis G, Boutati E, Lambadiari V, Mitrou P, Maratou E, Brunel P, et al. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest 2004; 34: 490-497.
-
(2004)
Eur J Clin Invest
, vol.34
, pp. 490-497
-
-
Dimitriadis, G.1
Boutati, E.2
Lambadiari, V.3
Mitrou, P.4
Maratou, E.5
Brunel, P.6
-
7
-
-
0031892659
-
Stimulation of insulin release by repaglinde and glibenclamide involves both common and distinct processes
-
Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinde and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
-
(1998)
Diabetes
, vol.47
, pp. 345-351
-
-
Fuhlendorff, J.1
Rorsman, P.2
Kofod, H.3
Brand, C.L.4
Rolin, B.5
MacKay, P.6
-
8
-
-
0141672120
-
Early-phase prandial insulin secretion: Its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide
-
Owens DR, Cozma LS, Luzio SD. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes Nutr Metab 2002; 15(6 Suppl): 19-27.
-
(2002)
Diabetes Nutr Metab
, vol.15
, Issue.6 SUPPL.
, pp. 19-27
-
-
Owens, D.R.1
Cozma, L.S.2
Luzio, S.D.3
-
9
-
-
1842334456
-
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
-
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
-
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20(Suppl 1): 1183-1197.
-
(1997)
Diabetes Care
, vol.20
, Issue.SUPPL. 1
, pp. 1183-1197
-
-
-
10
-
-
0038077476
-
The role of oral antidiabetic agents: Why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus
-
Standl E, Füchtenbusch M. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus. Diabetologia 2003; 46(Suppl 1): M30-M36.
-
(2003)
Diabetologia
, vol.46
, Issue.SUPPL. 1
-
-
Standl, E.1
Füchtenbusch, M.2
-
11
-
-
28244447065
-
Assessment and comparison of the efficacy and safety profiles of repaglinide and gliclazide in Korean patients with Type 2 diabetes
-
A440:1834 PO
-
Seol Kim Y, Lee HC, Han IK, Yeo JP, Jorgensen LN. Assessment and comparison of the efficacy and safety profiles of repaglinide and gliclazide in Korean patients with Type 2 diabetes. Diabetes 2001; 50 (Suppl 2) A440:1834 PO.
-
(2001)
Diabetes
, vol.50
, Issue.SUPPL. 2
-
-
Seol, K.Y.1
Lee, H.C.2
Han, I.K.3
Yeo, J.P.4
Jorgensen, L.N.5
-
12
-
-
0033592101
-
Glucose tolerance and mortality: Comparison of WHO and American Diabetic Association diagnostic criteria
-
The DECODE Study Group
-
The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617-621.
-
(1999)
Lancet
, vol.354
, pp. 617-621
-
-
-
13
-
-
1542708361
-
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents
-
Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med 2003; 20: 935-941.
-
(2003)
Diabet Med
, vol.20
, pp. 935-941
-
-
Furlong, N.J.1
Hulme, S.A.2
O'Brien, S.V.3
Hardy, K.J.4
-
14
-
-
77649238654
-
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus
-
Li Y, Xu L, Shen J, Ran J, Zhang Y, Wang M, et al. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Diabetes Res Clin Pract 2010; 88: 42-47.
-
(2010)
Diabetes Res Clin Pract
, vol.88
, pp. 42-47
-
-
Li, Y.1
Xu, L.2
Shen, J.3
Ran, J.4
Zhang, Y.5
Wang, M.6
-
15
-
-
0024602810
-
Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use
-
Melander A, Bitzén PO, Faber O, Groop L. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72.
-
(1989)
Drugs
, vol.37
, pp. 58-72
-
-
Melander, A.1
Bitzén, P.O.2
Faber, O.3
Groop, L.4
-
16
-
-
0022319015
-
Incidence of severe side effects during therapy with sulfonylureas and biguanides
-
Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 1985; 15: 111-115.
-
(1985)
Horm Metab Res
, vol.15
, pp. 111-115
-
-
Berger, W.1
-
17
-
-
34447511196
-
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
-
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
-
(2007)
JAMA
, vol.298
, pp. 299-308
-
-
Nordestgaard, B.G.1
Benn, M.2
Schnohr, P.3
Tybjaerg-Hansen, A.4
-
18
-
-
0032790119
-
Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes
-
Damsbo P, Marbury TC, Hatorp V, Clauson P, Müller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-39.
-
(1999)
Diabetes Res Clin Pract
, vol.45
, pp. 31-39
-
-
Damsbo, P.1
Marbury, T.C.2
Hatorp, V.3
Clauson, P.4
Müller, P.G.5
-
19
-
-
0027326414
-
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM
-
Wolffenbuttel BH, Nijst L, Sels JP, Menheere PP, Müller PG, Kruseman AC. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-116.
-
(1993)
Eur J Clin Pharmacol
, vol.45
, pp. 113-116
-
-
Wolffenbuttel, B.H.1
Nijst, L.2
Sels, J.P.3
Menheere, P.P.4
Müller, P.G.5
Kruseman, A.C.6
|